WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530568
CAS#: 2095432-55-4
Description: SR-18292 is a PGC-1α inhibitor. SR-18292 reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D.
MedKoo Cat#: 530568
Name: SR-18292
CAS#: 2095432-55-4
Chemical Formula: C23H30N2O2
Exact Mass: 366.2307
Molecular Weight: 366.505
Elemental Analysis: C, 75.37; H, 8.25; N, 7.64; O, 8.73
Related CAS #:
Synonym: SR-18292; SR 18292; SR18292.
IUPAC/Chemical Name: 1-((1H-indol-4-yl)oxy)-3-(tert-butyl(4-methylbenzyl)amino)propan-2-ol
InChi Key: BNRANURXPKRRKP-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H30N2O2/c1-17-8-10-18(11-9-17)14-25(23(2,3)4)15-19(26)16-27-22-7-5-6-21-20(22)12-13-24-21/h5-13,19,24,26H,14-16H2,1-4H3
SMILES Code: CC(C=C1)=CC=C1CN(C(C)(C)C)CC(O)COC2=CC=CC3=C2C=CN3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 366.505 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Sharabi K, Lin H, Tavares CD, Dominy JE, Camporez JP, Perry RJ, Schilling R,
Rines AK, Lee J, Hickey M, Bennion M, Palmer M, Nag PP, Bittker JA, Perez J,
Jedrychowski MP, Ozcan U, Gygi SP, Kamenecka TM, Shulman GI, Schreiber SL,
Griffin PR, Puigserver P. Selective Chemical Inhibition of PGC-1α Gluconeogenic
Activity Ameliorates Type 2 Diabetes. Cell. 2017 Mar 23;169(1):148-160.e15. doi:
10.1016/j.cell.2017.03.001. PubMed PMID: 28340340.
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. Targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D.
